Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK2 | O96017 | 1/20 | 0.49 |
| ▸ | PIK3CD | O00329 | 7/20 | 0.49 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.45 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.44 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.43 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.43 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.43 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.42 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26668718 | 1.00 | CHEK2 (0.49) | CHEK2PIK3CDUSP30GPR119IRAK1 | |
| SCHEMBL27117708 | 0.93 | PIK3CD (0.53) | PIK3CDUSP30GPR119 | |
| SCHEMBL26907427 | 0.93 | PIK3CD (0.53) | PIK3CDUSP30GPR119 | |
| SCHEMBL30722716 | 0.93 | PIK3CD (0.53) | PIK3CDUSP30GPR119 | |
| SCHEMBL26125483 | 0.88 | USP30 (0.45) | PIK3CDUSP30GPR119 | |
| SCHEMBL26668657 | 0.85 | GPR119 (0.54) | CHEK2PIK3CDGPR119HPGD | |
| SCHEMBL26668746 | 0.81 | CHEK2 (0.55) | CHEK2PIK3CDUSP30GPR119PDE4B | |
| SCHEMBL19023406 | 0.81 | USP30 (0.46) | PIK3CDUSP30GPR119HPGD | |
| SCHEMBL20281619 | 0.80 | CHEK2 (0.55) | CHEK2PIK3CDUSP30GPR119PDE4B | |
| SCHEMBL21604523 | 0.80 | CHEK2 (0.55) | CHEK2PIK3CDUSP30GPR119PDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230340011-A1 | STEROIDAL COMPOSITIONS AND METHODS OF TREATING LIPOGENIC CANCERS | Asteroid Therapeutics | 2023-10-26 | — | — | US | disclosed |
| US-20230340011-A1 | STEROIDAL COMPOSITIONS AND METHODS OF TREATING LIPOGENIC CANCERS | Asteroid Therapeutics | 2023-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230340011-A1 | STEROIDAL COMPOSITIONS AND METHODS OF TREATING LIPOGENIC CANCERS | SREBF1, SREBF2, NR1H3 | CHEK2 3290/4885PIK3CD 1833/4885USP30 2697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.